1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCalifornia Institute for Regenerative Medicine (CIRM) Preclinical Development (PDEV) Awards is sponsored by California Institute for Regenerative Medicine (CIRM). Supports completion of preclinical studies, FDA Investigational New Drug (IND) clearance, and clinical trial startup for innovative stem cell-based and genetic therapies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Preclinical Development (PDEV) Awards Accelerating Therapies to the Clinic Applications for the next PDEV funding cycle will open July/August 2026. The applications will be due in October 2026.
Photo Credit: City of Hope Preclinical Programs at CIRM CIRM’s Preclinical Development (PDEV) funding program supports completion of preclinical studies, FDA Investigational New Drug (IND) clearance, and clinical trial startup for innovative stem cell-based and genetic therapies. This partnership model helps applicants navigate key preclinical milestones and maximizes the likelihood of success.
This vision is achieved through a critical path approach emphasizing collaboration, knowledge sharing, and strategic alignment with CIRM’s broader goal of advancing 15 to 20 therapies into late-stage clinical trials. The awards may support a range of activities, from candidate optimization to IND-enabling studies and trial startup, ensuring a smooth path toward clinical readiness.
PDEV Awards: Key Information The expected outcome of all PDEV awards is the clearance of an IND application with the FDA for the stem cell-based or genetic therapy candidate. Below is a select list of eligibility requirements for reference. Applications must meet the complete list of eligibility requirements defined in the PDEV PA in order to be considered for CIRM funding.
The application must propose studies to support submission and clearance of a single IND application with the FDA for the proposed stem cell-based or genetic therapy The application must provide data demonstrating that reproducible disease-modifying activity was achieved with the proposed candidate The applicant organization must meet CIRM’s definition of a California Organization CIRM anticipates funding between 7-12 PDEV awards in FY26-27, contingent on the ratio of Early PDEV and Late PDEV applications recommended for funding.
The maximum total funding for a PDEV award is $13 million per award. The maximum award duration is 5 years. Applicants may request CIRM support for preclinical development activities spanning pre-IND and IND-enabling stages.
The maximum overall award amount and duration as well as expected funds requested and duration for each individual stage are described in the PA. How to Submit a Pre-submission Form: 1. Go to the Grants Management Portal 2.
After logging in, click on the Menu tab Navigate to “Open Programs” . Click on “Start a Pre-submission form for Preclinical Development Program (PDEV)” . 3.
Complete each section of the Pre-submission Form Click on the appropriate link and follow the posted instructions. Proposal outline templates can be located and submitted under the “Document Uploads” section. 4.
To submit your Pre-submission Form Click on the “Submit PDEV_Pre_Sub-XXXXX” button. The button will be enabled when all the mandatory sections have been completed. Note: Once submitted, you can no longer make changes to your pre-submission.
5. To confirm submission of your Pre-submission Form Select the tab labeled “Your Applications” and check the table under the section labeled “Your Submitted Applications. ” You will see your Pre-submission number and project title listed once the submission process has been completed.
Download the PDEV Program Announcement (PA) for more information on award eligibility, review criteria, and the application process. Download PDEV Program Announcement How to Submit an Application: 1. Go to the CIRM Grants Management Portal (grants.
cirm. ca. gov) 2.
After logging in, click on the Menu tab Select the tab labeled “Open Programs” under the section labeled “RFAs and Programs Open for Applications,” and click on the “Start a Grant Application” link for the selected program. 3. Complete each section of the Application Click on the appropriate link and follow the instructions.
Proposal templates can be located and submitted under the “Uploads” section. 4. To submit your Application Click on the “Done with Application” button.
After completing all the mandatory sections, the “Done with Application” button will be enabled. Note: Once submitted, you can no longer make changes to your application. 5.
To confirm submission of your Application Select the tab labeled “Your Applications” and check the table under the section labeled “Your Submitted Applications. ” Once the submission process has been completed, you will see your application number and project title listed. PDEV applications will open in late July or early August.
CIRM Grants Policies, FAQs, and Primers Data Sharing and Management Requirements Patient Access Planning Requirements Allowable Costs and co-funding FAQ Commercialization Rights Primer (IP, Revenue Sharing, Pricing, Access, March-in Rights) Grants Administration Policy for Clinical Stage Projects Preclinical Development Resources Industry Resource Partner Program CIRM California Academic Cell and Gene Therapy Manufacturing Network CIRM Alpha Clinics Network PDEV Application Resources Application Selection Process: Volume Control Video Application Selection Process: Volume Control Video Deck [PDF] PDEV FAQs [PDF | Updated July 1, 2026] PDEV Reference Application Proposal Template [PDF] PDEV Activity-Based Budget Guide [PDF] The applicant organization must be a California organization per CIRM’s definition.
A “California Organization” is a for-profit or non-profit organization or is a California-domiciled wholly owned subsidiary of a non-California organization (any entity that does not qualify as a California Organization) that meets all of the following criteria: Employment and Payroll: Employs at least one W-2 employee; and more than 50% of its W-2 employees, whether part-time or full-time, who are paid in any manner (e.g., wage, salary, commission, equity), must be domiciled full-time in California and be required to file California state income taxes due to their employment with the organization.
Management of Award Activities: The Principal Investigator (PI) must be physically located in California while overseeing all project activities.
Intellectual Property Rights: In the case of a California-domiciled wholly owned subsidiary of a non-California organization, the subsidiary must retain exclusive rights to any intellectual property arising out of the CIRM-funded project as well as any pre-existing IP rights held by the parent organization. What is the award amount and duration? The maximum total funding for a PDEV award is $13 million per award.
The maximum award duration is 5 years. Are Early PDEV and Late PDEV two separate awards and can I apply for just one stage of funding? Early PDEV (Pre-IND) and Late PDEV (IND-enabling) refer to the two stages of preclinical development encompassed by PDEV awards.
Projects that meet the candidate readiness eligibility criteria may request CIRM funding for Early and/or Late PDEV activities to achieve the expected outcome of IND clearance with the FDA for the proposed therapy. Applicants may not request funding solely for Early PDEV activities that won’t achieve the expected award outcome.
Applicants may request funding solely for Late PDEV activities if FDA pre-IND feedback has already been obtained for the proposed project. Do I need to have conducted a Pre-IND meeting to apply for PDEV? No. An applicant that meets PDEV eligibility criteria (i.e. candidate readiness) can apply for funding at any point to achieve the expected award outcome of IND clearance.
Who can I contact with any questions about PDEV? Programmatic questions regarding this award should be emailed to preclinical@cirm. ca.
gov with the subject line “PDEV”. Specific questions related to budget and Grants Administration policies should be emailed to grantsmanagement@cirm. ca.
gov with the subject line “PDEV”.
According to the current listing, eligibility includes: Small businesses engaged in stem cell-based and genetic therapies research. Confirm the full requirements in the official notice before applying.
Applications for California Institute for Regenerative Medicine (CIRM) Preclinical Development (PDEV) Awards are due October 1, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
California Institute for Regenerative Medicine (CIRM) Preclinical Development (PDEV) Awards is funded by California Institute for Regenerative Medicine (CIRM). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Preclinical Development (PDEV) program is sponsored by California Institute for Regenerative Medicine (CIRM). The PDEV program supports preclinical development of stem cell-based and genetic therapies that offer potential for transformative clinical impact and address current barriers to patient access. This includes research on stem cell-derived retinal pigment epithelium (RPE) cells for treating maculopathies and supporting photoreceptors.
CLIN2 Awards: Funding Opportunity for Clinical Trials is sponsored by California Institute for Regenerative Medicine (CIRM). CIRM's CLIN2 Awards program supports the clinical development of stem cell-based and genetic therapy approaches for treating diseases with unmet medical needs. The program aims to expedite clinical development towards late-stage trials through innovative trial designs and strategies for market access and pre-commercialization.
DARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleThe FY2026 MEP Center State Competition ran in two rounds: eight states worth $139.1 million, then fourteen more worth $232.4 million, both closing August 21, 2026. That's 43 percent of the national network recompeted in twelve months, under a 50 percent non-federal cost share, while the administration's own budget request proposed eliminating the program. Here's what the award tables reveal, why incumbents are genuinely at risk, and how to position for the FY2027 wave.
Read articleOn August 14, 2026, the California Arts Council approved nearly $24.6 million across 1,200 grant awards. Buried in the release is a rare thing: before-and-after data showing exactly how much the ranked-priority bonus moved the pool. Small organizations went from 53% of applicants to 72% of awardees. Geography moved 19 points. First-time status barely moved at all. Here is what that means for the 2027 cycle.
Read article